Cancer Research and Treatment

Review Article

Role of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy: Chang W Song, Hyunkyung Kim, Mi-Sook Kim, Heon J Park, Sun-Ha Paek, Stephanie Terezakis, L Chinsoo Cho; Cancer Res Treat. 2025;57(1):1-10. Published online June 5, 2024; DOI: https://doi.org/10.4143/crt.2024.255

Tumor microenvironment is intrinsically hypoxic with abundant hypoxia-inducible factors-1α (HIF-1α), a primary regulator of the cellular response to hypoxia and various stresses imposed on the tumor cells. HIF-1α increases radioresistance and chemoresistance by reducing DNA damage, increasing repair of DNA damage, enhancing glycolysis that increases antioxidant capacity of tumors cells, and promoting angiogenesis. In addition, HIF-1α markedly enhances drug efflux, leading to multidrug resistance. Radiotherapy and certain chemotherapy drugs evoke profound anti-tumor immunity by inducing immunologic cell death that release tumor-associated antigens together with numerous pro-immunological factors, leading to priming of cytotoxic CD8+ T cells and enhancing the cytotoxicity of macrophages and natural killer cells. Radiotherapy and chemotherapy of tumors significantly increase HIF-1α activity in tumor cells. Unfortunately, HIF-1α effectively promotes various immune suppressive pathways including secretion of immune suppressive cytokines, activation of myeloid-derived suppressor cells, activation of regulatory T cells, inhibition of T cells priming and activity, and upregulation of immune checkpoints. Consequently, the anti-tumor immunity elevated by radiotherapy and chemotherapy is counterbalanced or masked by the potent immune suppression promoted by HIF-1α. Effective inhibition of HIF-1α may significantly increase the efficacy of radiotherapy and chemotherapy by increasing radiosensitivity and chemosensitivity of tumor cells and also by upregulating anti-tumor immunity.

Citations

Citations to this article as recorded by

Down-regulation of PCK2 enhanced the radioresistance phenotype of nasopharyngeal carcinoma
Yijun He, Li Yan, Ruiqi Zhang, Rui Yang, Zhaolu Kong, Xiaosheng Wang
International Journal of Radiation Biology.2025; 101(5): 499. CrossRef
Hypoxia-Targeted Responsive Delivery of Doxorubicin and Digoxin for Synergistic Treatment of Triple-Negative Breast Cancer
Lingyan Weng, Min Zhao, Zhongping Chen, Li Zhu
Molecular Pharmaceutics.2025; 22(4): 2142. CrossRef

3,855 View
233 Download
3 Web of Science
2 Crossref

Original Articles

General

Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations: Kyung Hwan Kim, Han Sang Kim, Seung-seob Kim, Hyo Sup Shim, Andrew Jihoon Yang, Jason Joon Bock Lee, Hong In Yoon, Joong Bae Ahn, Jee Suk Chang; Cancer Res Treat. 2022;54(1):54-64. Published online June 4, 2021; DOI: https://doi.org/10.4143/crt.2020.1247

Abstract PDF Supplementary Material PubReader ePub

Purpose
Preclinical data indicate that response to radiotherapy (RT) depends on DNA damage repair. In this study, we investigated the role of mutations in genes related to DNA damage repair in treatment outcome after RT.
Materials and Methods
Patients with solid tumor who participated in next generation sequencing panel screening using biopsied tumor tissue between October 2013 and February 2019 were reviewed and 97 patients that received RT were included in this study. Best response to RT and the cumulative local recurrence rate (LRR) were compared according to absence or presence of missense, nonsense, and frameshift mutations in ATM and/or BRCA1/2.
Results
Of the 97 patients, five patients harbored mutation only in ATM, 22 in only BRCA1/2, and six in both ATM and BRCA1/2 (ATM^mtBRCA^mt). Propensity score matching was performed to select the control group without mutations (ATM^wtBRCA^wt, n=33). In total, 90 RT-treated target lesions were evaluated in 66 patients. Highest objective response rate of 80% was observed in ATM^mtBRCA^mt lesions (p=0.007), which was mostly durable. Furthermore, the cumulative 1-year LRR was the lowest in ATM^mtBRCA^mt lesions and the highest in ATM^wtBRCA^wt lesions (0% vs. 47.9%, p=0.008). RT-associated toxicities were observed in 10 treatments with no significant difference among the subgroups (p=0.680).
Conclusion
Tumors with ATM and BRCA1/2 mutations exhibited superior tumor response and local control after RT compared to tumors without these mutations. The results are hypothesis generating and suggest the need for integrating the tumor mutation profile of DNA repair genes during treatment planning.

Citations

Citations to this article as recorded by

The art of war: using genetic insights to understand and harness radiation sensitivity in hematologic malignancies
N. Ari Wijetunga, Joachim Yahalom, Brandon S. Imber
Frontiers in Oncology.2025;[Epub] CrossRef
Effects of Ataxia-Telangiectasia Mutated Variants on Radionecrosis and Local Control After Stereotactic Radiation Surgery for Non-Small Cell Lung Cancer Brain Metastases
Warren Floyd, David Carpenter, Eugene Vaios, Rachel Shenker, Peter Hendrickson, Justus D. Adamson, William M. Giles, Chunhao Wang, Karen Allen, Trey Mullikin, Scott R. Floyd, John P. Kirkpatrick, Michelle Green, Zachary J. Reitman
Advances in Radiation Oncology.2024; 9(1): 101320. CrossRef
Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma
Makiko Urabe, Kenji Ikezawa, Kazuhiro Kozumi, Yugo Kai, Ryoji Takada, Kaori Mukai, Tasuku Nakabori, Hiroyuki Uehara, Hirofumi Akita, Kazuyoshi Ohkawa
Clinical Journal of Gastroenterology.2024; 17(4): 771. CrossRef
Robustness of carbon‐ion radiotherapy against DNA damage repair associated radiosensitivity variation based on a biophysical model
Hans Liew, Thomas Tessonnier, Stewart Mein, Giuseppe Magro, Lars Glimelius, Elias Coniavitis, Thomas Held, Thomas Haberer, Amir Abdollahi, Jürgen Debus, Ivana Dokic, Andrea Mairani
Medical Physics.2024; 51(5): 3782. CrossRef
Use of Radiation Therapy for Ataxia-Telangiectasia Mutated (ATM)-Mutation Metastatic Renal Cell Carcinoma: A Case Report
Steven N Seyedin, Garrett Harada, Eleen Garemanian, Desiree Rafizadeh, Dalia Kaakour, Sami Dwabe, Michael Daneshvar, Nataliya Mar
Cureus.2024;[Epub] CrossRef
Star wars against leukemia: attacking the clones
Monika M. Toma, Tomasz Skorski
Leukemia.2024; 38(11): 2293. CrossRef
Predicting tumour radiosensitivity to deliver precision radiotherapy
James M. Price, Asmithaa Prabhakaran, Catharine M. L. West
Nature Reviews Clinical Oncology.2023; 20(2): 83. CrossRef
Locoregional Chemoradiation for a Patient with BRCA1 Stage IV Pancreatic Adenocarcinoma
Pranit Singh, Jacob Adams, Sylvia Choo, Matthew Adams, Jordan McDonald, Laura Barton, Richard Levine, Dae Won Kim, Russell Palm, Jessica Frakes, Sarah Hoffe
Applied Radiation Oncology.2023;[Epub] CrossRef
A genomic score to predict local control among patients with brain metastases managed with radiation
Nayan Lamba, Daniel N Cagney, Paul J Catalano, Dewey Kim, Hesham Elhalawani, Daphne A Haas-Kogan, Patrick Y Wen, Nikhil Wagle, Ayal A Aizer
Neuro-Oncology.2023; 25(10): 1815. CrossRef
Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution
Jarrell Imamura, Shinjini Ganguly, Andrew Muskara, Ross S. Liao, Jane K. Nguyen, Christopher Weight, Christopher E. Wee, Shilpa Gupta, Omar Y. Mian
Frontiers in Endocrinology.2023;[Epub] CrossRef
Ex Vivo Chromosomal Radiosensitivity Testing in Patients with Pathological Germline Variants in Breast Cancer High-Susceptibility Genes BReast CAncer 1 and BReast CAncer 2
Tara Zuhair Kassem, Marius Wunderle, Lukas Kuhlmann, Matthias Ruebner, Hanna Huebner, Juliane Hoyer, André Reis, Peter A. Fasching, Matthias W. Beckmann, Carolin C. Hack, Rainer Fietkau, Luitpold Distel
Current Issues in Molecular Biology.2023; 45(8): 6618. CrossRef
Moving the Needle Forward in Genomically-Guided Precision Radiation Treatment
Andrew Tam, Benjamin D. Mercier, Reeny M. Thomas, Eemon Tizpa, Irene G. Wong, Juncong Shi, Rishabh Garg, Heather Hampel, Stacy W. Gray, Terence Williams, Jose G. Bazan, Yun R. Li
Cancers.2023; 15(22): 5314. CrossRef
Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver
Winnie Li, Jeff Winter, Jerusha Padayachee, Jennifer Dang, Vickie Kong, Peter Chung
Frontiers in Oncology.2022;[Epub] CrossRef
Dramatic response to local radiotherapy in a refractory metastatic mediastinal yolk sac tumor patient harboring a germline BRCA2 frameshift mutation: a case report
Xi Cheng, Haiming Yu, Jinying Li, Xiaona Han, Erhong Meng, Houqing Zhou, Dongliang Wang, Beifang Niu, Xiaotao Zhang
Cancer Biology & Therapy.2022; 23(1): 393. CrossRef
Ovarian Cancer Radiosensitivity: What Have We Understood So Far?
Amelia Barcellini, Alexandra Charalampopoulou, Loris De Cecco, Andrei Fodor, Emanuela Rabaiotti, Giorgio Candotti, Simona Secondino, Angelica Facoetti, Laura Deborah Locati, Sandro Pignata, Ester Orlandi, Giorgia Mangili
Life.2022; 13(1): 6. CrossRef

9,724 View
238 Download
15 Web of Science
15 Crossref

A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset: Bum-Sup Jang, In Ah Kim; Cancer Res Treat. 2020;52(2):530-542. Published online November 20, 2019; DOI: https://doi.org/10.4143/crt.2019.440

Abstract PDF Supplementary Material PubReader ePub

Purpose
Combination of radiotherapy and immune checkpoint blockade such as programmed death- 1 (PD-1) or programmed death-ligand 1 (PD-L1) blockade is being actively tested in clinical trial. We aimed to identify a subset of patients that could potentially benefit from this strategy using The Cancer Genome Atlas (TCGA) dataset for glioblastoma (GBM).
Materials and Methods
A total of 399 cases were clustered into radiosensitive versus radioresistant (RR) groups based on a radiosensitivity gene signature and were also stratified as PD-L1 high versus PD-L1 low groups by expression of CD274 mRNA. Differential and integrated analyses with expression and methylation data were performed. CIBERSORT was used to enumerate the immune repertoire that resulted from transcriptome profiles.
Results
We identified a subset of GBM, PD-L1-high-RR group which showed worse survival compared to others. In PD-L1-high-RR, differentially expressed genes (DEG) were highly enriched for immune response and mapped into activation of phosphoinositide 3-kinase–AKT and mitogen-activated protein kinase (MAPK) signaling pathways. Integration of DEG and differentially methylated region identified that the kinase MAP3K8-involved in T-cell receptor signaling was upregulated and BAI1, a factor which inhibits angiogenesis, was silenced. CIBERSORT showed that a higher infiltration of the immune repertoire, which included M2 macrophages and regulatory T cells.
Conclusion
Taken together, PD-L1-high-RR group could potentially benefit from radiotherapy combined with PD-1/PD-L1 blockade and angiogenesis inhibition.

Citations

Citations to this article as recorded by

Clinical Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy: A Systematic Review
Christopher W. Bleaney, Hebatalla Abdelaal, Mark Reardon, Carmel Anandadas, Peter Hoskin, Ananya Choudhury, Laura Forker
Cancers.2024; 16(10): 1942. CrossRef
A retrospective cohort study of neoadjuvant chemoradiotherapy combined with immune checkpoint inhibitors in locally advanced rectal cancer
Zhuo Chen, Zhuoling Zou, Min Qian, Qin Xu, Guojuan Xue, Juan Yang, Tinglan Luo, Lianjie Hu, Bin Wang
Translational Oncology.2024; 44: 101955. CrossRef
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives
Hao Lin, Chaxian Liu, Ankang Hu, Duanwu Zhang, Hui Yang, Ying Mao
Journal of Hematology & Oncology.2024;[Epub] CrossRef
PSF-lncRNA interaction as a target for novel targeted anticancer therapies
Ren Liu, Xiaojing Wang, Min Zhou, Jingfang Zhai, Jie Sun
Biomedicine & Pharmacotherapy.2024; 180: 117491. CrossRef
Bladder Cancer Treatments in the Age of Personalized Medicine: A Comprehensive Review of Potential Radiosensitivity Biomarkers
Charbel Feghaly, Rafka Challita, Hanine Bou Hadir, Tala Mobayed, Tarek Al Bitar, Mohammad Harbi, Hala Ghorayeb, Rana El-Hassan, Larry Bodgi
Biomarker Insights.2024;[Epub] CrossRef
Improving the efficacy of combined radiotherapy and immunotherapy: focusing on the effects of radiosensitivity
Zhiru Gao, Qian Zhao, Yiyue Xu, Linlin Wang
Radiation Oncology.2023;[Epub] CrossRef
In Vivo Evaluation of Near-Infrared Fluorescent Probe for TIM3 Targeting in Mouse Glioma
Michael Zhang, Quan Zhou, Chinghsin Huang, Carmel T. Chan, Wei Wu, Gordon Li, Michael Lim, Sanjiv S. Gambhir, Heike E. Daldrup-Link
Molecular Imaging and Biology.2022; 24(2): 280. CrossRef
Relationship between Macrophage and Radiosensitivity in Human Primary and Recurrent Glioblastoma: In Silico Analysis with Publicly Available Datasets
Bum-Sup Jang, In Ah Kim
Biomedicines.2022; 10(2): 292. CrossRef
Optimal management of recurrent and metastatic upper tract urothelial carcinoma: Implications of intensity modulated radiation therapy
Mi Sun Kim, Woong Sub Koom, Jae Ho Cho, Se-Young Kim, Ik Jae Lee
Radiation Oncology.2022;[Epub] CrossRef
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
Daniel Kreatsoulas, Chelsea Bolyard, Bill X. Wu, Hakan Cam, Pierre Giglio, Zihai Li
Journal of Hematology & Oncology.2022;[Epub] CrossRef
The Next Frontier in Health Disparities—A Closer Look at Exploring Sex Differences in Glioma Data and Omics Analysis, from Bench to Bedside and Back
Maria Diaz Rosario, Harpreet Kaur, Erdal Tasci, Uma Shankavaram, Mary Sproull, Ying Zhuge, Kevin Camphausen, Andra Krauze
Biomolecules.2022; 12(9): 1203. CrossRef
Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
Thamiris Becker Scheffel, Nathália Grave, Pedro Vargas, Fernando Mendonça Diz, Liliana Rockenbach, Fernanda Bueno Morrone
Frontiers in Oncology.2021;[Epub] CrossRef
The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
Lu Meng, Jianfang Xu, Ying Ye, Yingying Wang, Shilan Luo, Xiaomei Gong
Frontiers in Immunology.2021;[Epub] CrossRef
Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy
Junjie Shen, Jingfang Liu, Huijun Li, Lu Bai, Zixuan Du, Ruirui Geng, Jianping Cao, Peng Sun, Zaixiang Tang
Radiation Oncology.2021;[Epub] CrossRef
Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on The Cancer Genome Atlas Dataset
Dongjun Dai, Yinglu Guo, Yongjie Shui, Jinfan Li, Biao Jiang, Qichun Wei
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Prognostic Values of Radiosensitivity Genes and CD19 Status in Gastric Cancer: A Retrospective Study Using TCGA Database

Li-Bo Liang, Xin-Yan Huang, He He, Ji-Yan Liu
Pharmacogenomics and Personalized Medicine.2020; Volume 13: 365. CrossRef
Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma
Linzhi Han, Hongjie Shi, Yuan Luo, Wenjie Sun, Shuying Li, Nannan Zhang, Xueping Jiang, Yan Gong, Conghua Xie
Cancer Medicine.2020; 9(24): 9581. CrossRef

7,891 View
261 Download
19 Web of Science
17 Crossref

Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro: Hyeon Kang Koh, Soo Yeon Seo, Jin Ho Kim, Hak Jae Kim, Eui Kyu Chie, Seung-Ki Kim, Il Han Kim; Cancer Res Treat. 2019;51(2):696-705. Published online August 13, 2018; DOI: https://doi.org/10.4143/crt.2018.249

Abstract PDF PubReader ePub

Purpose
Glioblastoma, the most common brain tumor in adults, has poor prognosis. The purpose of this study was to determine the effect of disulfiram (DSF), an aldehyde dehydrogenase inhibitor, on in vitro radiosensitivity of glioblastoma cells with different methylation status of O⁶-methylguanine-DNA methyltransferase (MGMT) promoter and the underlying mechanism of such effect.
Materials and Methods
Five human glioblastoma cells (U138MG, T98G, U251MG, U87MG, and U373MG) and one normal human astrocyte (NHA) cell were cultured and treated with DSF or 6MV X-rays (0, 2, 4, 6, and 8 Gy). For combined treatment, cells were treated with DSF before irradiation. Surviving fractions fit from cell survival based on colony forming ability. Apoptosis, DNA damage repair, and cell cycle distributionwere assayed bywestern blot for cleaved caspase-3, γH2AX staining, and flow cytometry, respectively.
Results
DSF induced radiosensitization in most of the glioblastoma cells, especially, in the cells with radioresistance as wildtype unmethylated promoter (MGMT-wt), but did not in normal NHA cell. DSF augmented or induced cleavage of caspase-3 in all cells after irradiation. DSF inhibited repair of radiation-induced DNA damage in MGMT-wt cells, but not in cells with methylated MGMT promoter. DSF abrogated radiation-induced G2/M arrest in T98G and U251MG cells.
Conclusion
Radiosensitivity of glioblastoma cells were preferentially enhanced by pre-irradiation DSF treatment compared to normal cell, especially radioresistant cells such as MGMT-wt cells. Induction of apoptosis or inhibition of DNA damage repair may underlie DSF-induced radiosensitization. Clinical benefit of combining DSF with radiotherapy should be investigated in the future.

Citations

Citations to this article as recorded by

The role of KDM4A‐mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis
Xi‐Xi Li, Jia‐Kun Xu, Wei‐Jie Su, Hong‐Lin Wu, Kun Zhao, Chang‐Ming Zhang, Xiang‐Kun Chen, Li‐Xuan Yang
The Kaohsiung Journal of Medical Sciences.2024; 40(2): 161. CrossRef
Glioblastoma Therapy: Past, Present and Future
Elena Obrador, Paz Moreno-Murciano, María Oriol-Caballo, Rafael López-Blanch, Begoña Pineda, Julia Gutiérrez-Arroyo, Alba Loras, Luis Gonzalez-Bonet, Conrado Martinez-Cadenas, José Estrela, María Marqués-Torrejón
International Journal of Molecular Sciences.2024; 25(5): 2529. CrossRef
Exploring Disulfiram’s Anticancer Potential: PLGA Nano-Carriers for Prolonged Drug Delivery and Potential Improved Therapeutic Efficacy
Ibrahim Dumbuya, Ana Maria Pereira, Ibrahim Tolaymat, Adnan Al Dalaty, Basel Arafat, Matt Webster, Barbara Pierscionek, Mouhamad Khoder, Mohammad Najlah
Nanomaterials.2024; 14(13): 1133. CrossRef
Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma
Rafael Jiménez, Andrada Constantinescu, Muhube Yazir, Paula Alfonso-Triguero, Raquel Pequerul, Xavier Parés, Mileidys Pérez-Alea, Ana Paula Candiota, Jaume Farrés, Julia Lorenzo
International Journal of Molecular Sciences.2024; 25(21): 11512. CrossRef
Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review
Beáta-Mária Benkő, Dimitrios A. Lamprou, Anna Sebestyén, Romána Zelkó, István Sebe
Expert Opinion on Drug Delivery.2023; 20(4): 541. CrossRef
Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma
Katja Werlenius, Sara Kinhult, Tora Skeidsvoll Solheim, Henriette Magelssen, David Löfgren, Munila Mudaisi, Sofia Hylin, Jiri Bartek, Michael Strandéus, Magnus Lindskog, Havyan Bahroz Rashid, Louise Carstam, Sasha Gulati, Ole Solheim, Jiri Bartek, Øyvind
JAMA Network Open.2023; 6(3): e234149. CrossRef
Drug repositioning of disulfiram induces endometrioid epithelial ovarian cancer cell death via the both apoptosis and cuproptosis pathways
YAPING GAN, TING LIU, WEIFENG FENG, LIANG WANG, LI LI, YINGXIA NING
Oncology Research.2023; 31(3): 333. CrossRef
Disulfiram/Copper induces antitumor activity against gastric cancer via the ROS/MAPK and NPL4 pathways
Yao Liu, Xin Guan, Meiling Wang, Naixue Wang, Yutong Chen, Baolei Li, Zhuxuan Xu, Fangwei Fu, Cheng Du, Zhendong Zheng
Bioengineered.2022; 13(3): 6579. CrossRef
Disulfiram in glioma: Literature review of drug repurposing
Shiyu Zhong, Shengyu Liu, Xin Shi, Xudong Zhang, Kunhang Li, Guojun Liu, Lishuai Li, Shanwei Tao, Bowen Zheng, Weichen Sheng, Ziyin Ye, Qichen Xing, Qingqing Zhai, Lijie Ren, Ying Wu, Yijun Bao
Frontiers in Pharmacology.2022;[Epub] CrossRef
Multimodal targeting of glioma with functionalized nanoparticles
Hany E. Marei
Cancer Cell International.2022;[Epub] CrossRef
Formulation Comprising Arsenic Trioxide and Dimercaprol Enhances Radiosensitivity of Pancreatic Cancer Xenografts
Renyan Tang, Jianmin Zhu, Ying Liu, Ning Wu, Jinbin Han
Technology in Cancer Research & Treatment.2021;[Epub] CrossRef
Antioxidant and Antiproliferative Activity of Finasteride against Glioblastoma Cells
Hyeon Ji Kim, Tae-Jun Kim, Yu Gyung Kim, Chaeeun Seong, Jin-Hwa Cho, Wanil Kim, Kyung-Ha Lee, Do-Yeon Kim
Pharmaceutics.2021; 13(9): 1410. CrossRef
Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor
Chan-Chuan Liu, Cheng-Lin Wu, Meng-Xuan Lin, Chun-I Sze, Po-Wu Gean
International Journal of Molecular Sciences.2021; 22(19): 10496. CrossRef
Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study
Lisa Zirjacks, Nicolai Stransky, Lukas Klumpp, Lukas Prause, Franziska Eckert, Daniel Zips, Sabine Schleicher, Rupert Handgretinger, Stephan M. Huber, Katrin Ganser
Biomolecules.2021; 11(11): 1561. CrossRef
The combination of disulfiram and copper for cancer treatment
Hong Li, Jingyu Wang, Chunfu Wu, Lihui Wang, Zhe-Sheng Chen, Wei Cui
Drug Discovery Today.2020; 25(6): 1099. CrossRef
Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme
Jinyeong Choi, Gaeun Kim, Su Bin Cho, Hyung-Jun Im
Journal of Nanobiotechnology.2020;[Epub] CrossRef
Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos?
Francisco Meraz-Torres, Sarah Plöger, Claus Garbe, Heike Niessner, Tobias Sinnberg
Cancers.2020; 12(12): 3538. CrossRef
Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents
Elmira Ekinci, Sagar Rohondia, Raheel Khan, Qingping P. Dou
Recent Patents on Anti-Cancer Drug Discovery.2019; 14(2): 113. CrossRef

9,742 View
297 Download
20 Web of Science
18 Crossref

Longitudinal Assessment of Intravoxel Incoherent Motion Diffusion Weighted Imaging in Evaluating the Radio-sensitivity of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy: Youping Xiao, Ying Chen, Yunbin Chen, Zhuangzhen He, Yiqi Yao, Jianji Pan; Cancer Res Treat. 2019;51(1):345-356. Published online May 14, 2018; DOI: https://doi.org/10.4143/crt.2018.089

Abstract PDF PubReader ePub

Purpose
Intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI)was evaluated regarding its ability to preliminarily predict the short-term treatment response of nasopharyngeal carcinoma (NPC) following intensity-modulated radiation therapy.
Materials and Methods
IVIM-DWI with 14 b-factors (0-1,000 sec/mm2 ) was performed with a 3T MR system on 47 consecutive NPCs before, during (end of the 5th, 10th, 15th, 20th, and 25th fractions), and after fractional radiotherapy. IVIM parametrics (D, f, and D*) were calculated and compared to the baseline and xth fraction. Patients were categorized into responders and non-responders after radiotherapy. IVIM parametrics were also compared between subgroups.
Results
After fractional radiations, the D (except D5 and D at the end of the 5th fraction) after radiations were larger than the baseline D0 (p < 0.05), and the post-radiation D* (except D*5 and D*10) were smaller than D*0 (p < 0.05). f0 was smaller than f5 and f10 (p < 0.001) but larger than fend (p < 0.05). Furthermore, greater D5, D10, D15, and f10 coupled with smaller f0, D*20, and D*25were observed in responders than non-responders (all p < 0.01). Responders also presented larger ΔD10, Δf10, ΔD*20, and δD*20 than non-responders (p < 0.05). Receiver operating characteristic curve analysis indicated that the D5, D*20, and f10 could better differentiate responders from non-responders.
Conclusion
IVIM-DWI could efficiently assess tumor treatment response to fractional radiotherapy and predict the radio-sensitivity for NPCs.

Citations

Citations to this article as recorded by

Intravoxel incoherent motion magnetic resonance imaging to assess early tumor response to radiation therapy: Review and future directions
Emmanuel Mesny, Benjamin Leporq, Olivier Chapet, Olivier Beuf
Magnetic Resonance Imaging.2024; 108: 129. CrossRef
Prediction of short-term treatment outcome of nasopharyngeal carcinoma based on voxel incoherent motion imaging and arterial spin labeling quantitative parameters
Liping Liao, Teng Liu, Bo Wei
European Journal of Radiology Open.2023; 10: 100466. CrossRef
A review of diffusion-weighted magnetic resonance imaging in head and neck cancer patients for treatment evaluation and prediction of radiation-induced xerostomia
Tai Ermongkonchai, Richard Khor, Morikatsu Wada, Eddie Lau, Daniel Tao Xing, Sweet Ping Ng
Radiation Oncology.2023;[Epub] CrossRef
Intravoxel incoherent motion radiomics nomogram for predicting tumor treatment responses in nasopharyngeal carcinoma
Yihao Guo, Ganmian Dai, Xiaoli Xiong, Xiaoyi Wang, Huijuan Chen, Xiaoyue Zhou, Weiyuan Huang, Feng Chen
Translational Oncology.2023; 31: 101648. CrossRef
Amide proton transfer (APT) and magnetization transfer (MT) in predicting short-term therapeutic outcome in nasopharyngeal carcinoma after chemoradiotherapy: a feasibility study of three-dimensional chemical exchange saturation transfer (CEST) MRI
Wenguang Liu, Xiao Wang, Simin Xie, Weiyin Vivian Liu, Ismail Bilal Masokano, Yu Bai, Juan Chen, Linhui Zhong, Yijing Luo, Gaofeng Zhou, Wenzheng Li, Yigang Pei
Cancer Imaging.2023;[Epub] CrossRef
Baseline Amide Proton Transfer Imaging at 3T Fails to Predict Early Response to Induction Chemotherapy in Nasopharyngeal Carcinoma
Zhou Liu, Liyan Zou, Qian Yang, Long Qian, Tianran Li, Honghong Luo, Canwen Che, Yuanyuan Lei, Peng Chen, Chunyan Qiu, Xin Liu, Yin Wu, Dehong Luo
Frontiers in Oncology.2022;[Epub] CrossRef
Arterial spin labeling of nasopharyngeal carcinoma shows early therapy response
Jun Liu, Juan Zhu, Yaxian Wang, Fei Wang, Hualin Yang, Nan Wang, Qingyun Chu, Qing Yang
Insights into Imaging.2022;[Epub] CrossRef
A comparative study of functional MRI in predicting response of regional nodes to induction chemotherapy in patients with nasopharyngeal carcinoma
Dawei Zhao, Xuemei Fang, Wenjun Fan, Lingling Meng, Yanrong Luo, Nanxiang Chen, Jinfeng Li, Xiao Zang, Meng Li, Xingdong Guo, Biyang Cao, Chenchen Wu, Xin Tan, Boning Cai, Lin Ma
Frontiers in Oncology.2022;[Epub] CrossRef
The value of intravoxel incoherent motion model-based diffusion-weighted imaging for predicting long-term outcomes in nasopharyngeal carcinoma
Yuhui Qin, Chen Chen, Haotian Chen, Fabao Gao
Frontiers in Oncology.2022;[Epub] CrossRef
Au-Pt Nanoparticle Formulation as a Radiosensitizer for Radiotherapy with Dual Effects
Song Yang, Gaohua Han, Quan Chen, Lei Yu, Peng Wang, Qi Zhang, Jiang Dong, Wei Zhang, Junxing Huang
International Journal of Nanomedicine.2021; Volume 16: 239. CrossRef
Diffusion-weighted MRI for predicting treatment response in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis
Min Kyoung Lee, Yangsean Choi, So-Lyung Jung
Scientific Reports.2021;[Epub] CrossRef
Application Value of Magnetic Resonance Radiomics and Clinical Nomograms in Evaluating the Sensitivity of Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
Chunmiao Hu, Dechun Zheng, Xisheng Cao, Peipei Pang, Yanhong Fang, Tao Lu, Yunbin Chen
Frontiers in Oncology.2021;[Epub] CrossRef
Comparison of the pre-treatment functional MRI metrics’ efficacy in predicting Locoregionally advanced nasopharyngeal carcinoma response to induction chemotherapy
Da-wei Zhao, Wen-jun Fan, Ling-ling Meng, Yan-rong Luo, Jian Wei, Kun Liu, Gang Liu, Jin-feng Li, Xiao Zang, Meng Li, Xin-xin Zhang, Lin Ma
Cancer Imaging.2021;[Epub] CrossRef
Early detection treatment response for head and neck carcinomas using intravoxel incoherent motion-magnetic resonance imaging: a meta-analysis
Qingxu Song, Fang Li, Xin Chen, Jianbo Wang, Hong Liu, Yufeng Cheng
Dentomaxillofacial Radiology.2020; : 20190507. CrossRef
Pre-treatment intravoxel incoherent motion diffusion-weighted imaging predicts treatment outcome in nasopharyngeal carcinoma
Sahrish Qamar, Ann D. King, Qi-Yong H. Ai, Tiffany Y. So, Frankie Kwok Fai Mo, Weitian Chen, Darren M.C. Poon, Macy Tong, Brigette B. Ma, Edwin P. Hui, David Ka-Wai Yeung, Yi-Xiang Wang, Jing Yuan
European Journal of Radiology.2020; 129: 109127. CrossRef
Advanced magnetic resonance imaging techniques for tumors of the head and neck
E. Santos Armentia, T. Martín Noguerol, V. Suárez Vega
Radiología (English Edition).2019; 61(3): 191. CrossRef

8,890 View
174 Download
17 Web of Science
16 Crossref

DNA Methyltransferase Gene Polymorphisms for Prediction of Radiation-Induced Skin Fibrosis after Treatment of Breast Cancer: A Multifactorial Genetic Approach: Salvatore Terrazzino, Letizia Deantonio, Sarah Cargnin, Laura Donis, Carla Pisani, Laura Masini, Giuseppina Gambaro, Pier Luigi Canonico, Armando A. Genazzani, Marco Krengli; Cancer Res Treat. 2017;49(2):464-472. Published online August 23, 2016; DOI: https://doi.org/10.4143/crt.2016.256

Abstract PDF PubReader ePub

Purpose
This study was conducted to investigate the role of four polymorphic variants of DNA methyltransferase genes as risk factors for radiation-induced fibrosis in breast cancer patients. We also assessed their ability to improve prediction accuracy when combined with mitochondrial haplogroup H, which we previously found to be independently associated with a lower hazard of radiation-induced fibrosis.
Materials and Methods
DNMT1 rs2228611,DNMT3A rs1550117,DNMT3A rs7581217, and DNMT3B rs2424908 were genotyped by real-time polymerase chain reaction in 286 Italian breast cancer patients who received radiotherapy after breast conserving surgery. Subcutaneous fibrosis was scored according to the Late Effects of Normal Tissue–Subjective Objective Management Analytical (LENT-SOMA) scale. The discriminative accuracy of genetic models was assessed by the area under the receiver operating characteristic curves (AUC).
Results
Kaplan-Meier curves showed significant differences among DNMT1 rs2228611 genotypes in the cumulative incidence of grade ≥ 2 subcutaneous fibrosis (log-rank test p-value= 0.018). Multivariate Cox regression analysis revealed DNMT1 rs2228611 as an independent protective factor for moderate to severe radiation-induced fibrosis (GG vs. AA; hazard ratio, 0.26; 95% confidence interval [CI], 0.10 to 0.71; p=0.009). Adding DNMT1 rs2228611 to haplogroup H increased the discrimination accuracy (AUC) of the model from 0.595 (95% CI, 0.536 to 0.653) to 0.655 (95% CI, 0.597 to 0.710).
Conclusion
DNMT1 rs2228611 may represent a determinant of radiation-induced fibrosis in breast cancer patients with promise for clinical usefulness in genetic-based predictive models.

Citations

Citations to this article as recorded by

DNMT3A and DNMT3B in Breast Tumorigenesis and Potential Therapy
Xiaxia Man, Qi Li, Baogang Wang, He Zhang, Songling Zhang, Ziyi Li
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
DNMT1 Enhances the Radiosensitivity of HPV-Positive Head and Neck Squamous Cell Carcinomas via Downregulating SMG1

Chunlin Zhang, Jiaoping Mi, Yuan Deng, Zeyi Deng, Dan Long, Zhaohui Liu
OncoTargets and Therapy.2020; Volume 13: 4201. CrossRef
Betulinic Acid and Brosimine B Hybrid Derivatives as Potential Agents against Female Cancers
Nádia M. Garcês de Couto, Júlia B. Willig, Thaís C. Ruaro, Diogo Losch de Oliveira, Andréia Buffon, Diogo A. Pilger, Mara S.P. Arruda, Diogo Miron, Aline R. Zimmer, Simone C.B. Gnoatto
Anti-Cancer Agents in Medicinal Chemistry.2020; 20(5): 622. CrossRef
Reactive Oxygen Species Drive Epigenetic Changes in Radiation-Induced Fibrosis
Shashank Shrishrimal, Elizabeth A. Kosmacek, Rebecca E. Oberley-Deegan
Oxidative Medicine and Cellular Longevity.2019; 2019: 1. CrossRef
Impact of ATM rs1801516 on late skin reactions of radiotherapy for breast cancer: Evidences from a cohort study and a trial sequential meta-analysis
Salvatore Terrazzino, Sarah Cargnin, Letizia Deantonio, Carla Pisani, Laura Masini, Pier Luigi Canonico, Armando A. Genazzani, Marco Krengli, Christophe Badie
PLOS ONE.2019; 14(11): e0225685. CrossRef
Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population
Jennifer J. Hu, James J. Urbanic, L. Doug Case, Cristiane Takita, Jean L. Wright, Doris R. Brown, Carl D. Langefeld, Mark O. Lively, Sandra E. Mitchell, Anu Thakrar, David Bryant, Kathy Baglan, Jon Strasser, Luis Baez-Diaz, Glenn J. Lesser, Edward G. Shaw
Journal of Clinical Oncology.2018; 36(24): 2473. CrossRef

10,207 View
256 Download
7 Web of Science
6 Crossref

Case Report

Palliative Radiotherapy in a Patient with Pulmonary Adenoid Cystic Carcinoma: BoKyong Kim; Cancer Res Treat. 2007;39(4):185-188. Published online December 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.4.185

Abstract PDF PubReader ePub

Primary adenoid cystic carcinoma in the lung is very rare, so its clinicopathologic characteristics have usually been extrapolated from the salivary disease. However, the clinical courses of pulmonary adenoid cystic carcinomas may be different from those of salivary disease, and individual differences may also exist. I report here on a case of a patient who was initially diagnosed as pulmonary adenoid cystic carcinoma with liver metastases and the tumor showed extreme radiosensitivity, but it also underwent an aggressive clinical course. Adenoid cystic carcinoma is usually known to be a slowly growing tumor, but it may rapidly disseminate, like in this patient. Therefore, the factors predicting aggressive behavior should be determined and the treatment might be individualized according to the primary sites and on the patient's basis.

Citations

Citations to this article as recorded by

Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological features and molecular alterations in twenty-one cases
Zhiyuan Yao, Tong Qiu, Changlei Li, Weimao Kong, Guangqi Li, Peng Song, Guohua Wang, Wenjie Jiao
Lung Cancer.2025; 201: 108414. CrossRef
A Case of Undetermined Adenoid Cystic Carcinoma With Airway Stenosis Treated With Palliative X-Ray Radiotherapy Leading to Significant Improvement in Patient’s General Condition
Nobuko Utsumi, Masafumi Inoue, Kosei Miura
Cureus.2023;[Epub] CrossRef
Stereotactic body radiotherapy for adenoid cystic carcinoma metastatic to the lung: a case report
Daijiro Kobayashi, Takanori Abe, Jun-ichi Saitoh, Takahiro Oike, Hiro Sato, Atsushi Musha, Tatsuji Mizukami, Tsuneo Shimizu, Takashi Nakano, Tatsuya Ohno
Journal of Medical Case Reports.2021;[Epub] CrossRef
Apigenin inhibits the proliferation of adenoid cystic carcinoma via suppression of glucose transporter-1
JIN FANG, YANG-YANG BAO, SHUI-HONG ZHOU, JUN FAN
Molecular Medicine Reports.2015; 12(5): 6461. CrossRef
Primary adenoid cystic carcinoma of the bronchus in a female teenager
I Masih, G Porter, S Porter, R Clarke, P Sidhu, J Harney, A McCarthy, R Convery
BMJ Case Reports.2010; 2010: bcr0820103252. CrossRef

8,719 View
61 Download
5 Crossref

First
Prev
Page of 1
Next
Last

Search